Halladay Benjamin (CIK 1953943) reported 12 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-18). Recent activity: Sell ESPR (10,773 shares), Sell ESPR (6,424 shares), Buy ESPR (247,430 shares), Sell ESPR (7,337 shares), Sell ESPR (7,046 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 10,773 | $33,989 |
| 2026-03-18 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 6,424 | $17,409 |
| 2026-03-16 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Buy | 247,430 | $0 |
| 2025-12-18 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 7,337 | $26,927 |
| 2025-09-18 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 7,046 | $19,799 |
| 2025-07-18 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 11 | $12 |
| 2025-06-18 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 7,229 | $8,313 |
| 2025-04-21 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 8 | $8 |
| 2025-03-19 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 3,535 | $5,232 |
| 2025-03-17 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Buy | 238,000 | $0 |
| 2025-02-20 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 11 | $20 |
| 2025-01-21 | Esperion Therapeutics, Inc. (ESPR) | Chief Financial Officer | Sell | 9 | $20 |
Source: SEC Form 4 filings · as of 2026-06-18